Savara’s primary focus is IMPALA 2, a second Phase 3 clinical study of Molgradex for the treatment of autoimmune pulmonary alveolar proteinosis (aPAP). The company is also conducting another pivotal Phase 3 study, called AVAIL, that is evaluating AeroVanc for the treatment of MRSA in people living with cystic fibrosis.
When you visit any web site, it may store or retrieve information on your browser, mostly in the form of cookies. Control your personal Cookie Services here.
Google Analytics works by means of tracking code that is added to the pages of our website. Every user is registered with a unique ID, so that Google Analytics can provide us with insight into how many unique visitors there are to the site, for example, and how many users return.
With Google Analytics, we can survey how often any single user has visited the website, what pages they visited, for how long they stayed and how they interacted with the site.
